Cardiol Financial Statements From 2010 to 2024

Stocks USA . 
Stock . Cardiol Therapeutics Class
CRDL Stock  USD 1.33  0.03  2.21%   
Cardiol Therapeutics financial statements provide useful quarterly and yearly information to potential Cardiol Therapeutics Class investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cardiol Therapeutics financial statements helps investors assess Cardiol Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cardiol Therapeutics' valuation are summarized below:
Gross Profit
78.8 K
Market Capitalization
116.9 M
Enterprise Value Revenue
178.8107
Earnings Share
(0.38)
There are over one hundred nineteen available fundamental signals for Cardiol Therapeutics Class, which can be analyzed over time and compared to other ratios. We recommend to validate Cardiol Therapeutics' prevailing fundamental drivers against the all of the trends between 2010 and 2024. Market Cap is expected to rise to about 93.1 M this year, although Enterprise Value is projected to rise to (17.8 M).
Check Cardiol Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardiol Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 2.3 M, Interest Income of 2.3 M or Depreciation And Amortization of 182.4 K, as well as many indicators such as Price To Sales Ratio of 1 K, Dividend Yield of 0.0 or PTB Ratio of 2.38. Cardiol financial statements analysis is a perfect complement when working with Cardiol Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cardiol Therapeutics Correlation against competitors.

Cardiol Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets38.6 M36.7 M20.5 M
Slightly volatile
Short and Long Term Debt Total133.9 K174.3 K175.7 K
Slightly volatile
Other Current Liabilities622.2 K655 K766.5 K
Slightly volatile
Total Current Liabilities5.5 M8.3 M2.8 M
Slightly volatile
Total Stockholder Equity33 M28.2 M17.5 M
Slightly volatile
Net Tangible Assets32.7 M59.7 M19.1 M
Slightly volatile
Property Plant And Equipment Net329.6 K337.1 K170.6 K
Slightly volatile
Accounts Payable3.9 M7.6 M2 M
Slightly volatile
Cash34.3 M34.9 M17.9 M
Slightly volatile
Non Current Assets Total610.6 K547.4 K740.3 K
Pretty Stable
Long Term Debt252.6 K309.6 K228.6 K
Slightly volatile
Cash And Short Term Investments34.3 M34.9 M17.9 M
Slightly volatile
Net Receivables452.2 K279.9 K269.5 K
Slightly volatile
Common Stock Shares Outstanding41.5 M64.5 M31 M
Slightly volatile
Liabilities And Stockholders Equity38.6 M36.7 M20.5 M
Slightly volatile
Non Current Liabilities Total109.5 K158.5 K159.9 K
Slightly volatile
Other Stockholder Equity10 M18.8 M5.1 M
Slightly volatile
Total Liabilities5.7 M8.5 M3 M
Slightly volatile
Net Invested Capital33.4 M60 M19.8 M
Slightly volatile
Total Current Assets37.8 M36.2 M19.7 M
Slightly volatile
Net Working Capital32.5 M59.4 M19 M
Slightly volatile
Intangible Assets371 K210.4 K575.7 K
Slightly volatile
Common Stock89.8 M148.5 M46.1 M
Slightly volatile
Property Plant Equipment322.7 K340.1 K170.3 K
Slightly volatile
Other Current Assets1.6 M1.2 M1.1 M
Slightly volatile
Capital Stock92.1 M169.7 M64.9 M
Slightly volatile
Short Term Investments67.8 K71.2 K62.4 K
Slightly volatile
Capital Lease Obligations107.6 K65.6 K161.8 K
Slightly volatile
Property Plant And Equipment Gross787.5 K906.9 K700.1 K
Slightly volatile
Accumulated Other Comprehensive Income3.8 M4 M2.5 M
Slightly volatile
Short Term Debt15 K15.8 K45.5 K
Slightly volatile
Other Assets0.80.90.98
Slightly volatile

Cardiol Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income2.3 M2.2 M418.4 K
Slightly volatile
Depreciation And Amortization182.4 K195.3 K114.4 K
Slightly volatile
Selling General Administrative14.6 M15.6 M7.7 M
Slightly volatile
Other Operating Expenses24.2 M29.8 M12.6 M
Slightly volatile
Research Development9.4 M14.2 M4.8 M
Slightly volatile
Total Operating Expenses24.2 M29.8 M12.6 M
Slightly volatile
Reconciled Depreciation189.3 K239.6 K117.8 K
Slightly volatile
Cost Of Revenue233.3 K248.4 K177.1 K
Slightly volatile
Selling And Marketing Expenses12.2 M13.8 M15 M
Slightly volatile

Cardiol Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation23624889.3 K
Slightly volatile
Capital Expenditures61.0964.3153.3 K
Very volatile
End Period Cash Flow33.2 K34.9 K13.3 M
Slightly volatile
Stock Based Compensation4.7 M4.2 M2.9 M
Slightly volatile
Issuance Of Capital Stock39.4 M71.4 M26.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1 K1.2 K1.3 K
Slightly volatile
PTB Ratio2.382.510419.2414
Slightly volatile
Days Sales Outstanding1.5 K1.7 K1.8 K
Slightly volatile
Book Value Per Share0.640.43820.4763
Slightly volatile
Average Payables2 M1.9 M1.3 M
Slightly volatile
Stock Based Compensation To Revenue86.3297.11106
Slightly volatile
Capex To Depreciation2.0E-43.0E-40.528
Pretty Stable
PB Ratio2.382.510419.2414
Slightly volatile
EV To Sales172193211
Slightly volatile
Inventory Turnover12.0711.54.1439
Slightly volatile
Days Of Inventory On Hand31.2132.8615.4 K
Slightly volatile
Payables Turnover0.02250.023726.6995
Pretty Stable
Sales General And Administrative To Revenue283319347
Slightly volatile
Average Inventory2.8 M3.4 M3.3 M
Slightly volatile
Research And Ddevelopement To Revenue110124135
Slightly volatile
Capex To Revenue0.130.150.1608
Slightly volatile
Cash Per Share0.620.54280.448
Slightly volatile
Days Payables Outstanding13.1 K12.5 K4.8 K
Slightly volatile
Income Quality9.0E-49.0E-40.6541
Slightly volatile
Intangibles To Total Assets0.00540.00570.1261
Slightly volatile
Net Debt To EBITDA1.031.24721.3241
Very volatile
Current Ratio4.144.358211.5172
Slightly volatile
Tangible Book Value Per Share0.630.43490.4525
Slightly volatile
Receivables Turnover0.150.170.189
Slightly volatile
Graham Number3.182.07411.7723
Slightly volatile
Shareholders Equity Per Share0.640.43820.4763
Slightly volatile
Debt To Equity0.00610.00650.0387
Slightly volatile
Capex Per Share0.00.00.002
Very volatile
Graham Net Net0.550.4150.4008
Slightly volatile
Average Receivables524.7 K437 K535.6 K
Slightly volatile
Revenue Per Share0.00150.00160.0018
Slightly volatile
Interest Debt Per Share0.00270.00280.0108
Pretty Stable
Debt To Assets0.00470.0050.034
Slightly volatile
Price Book Value Ratio2.382.510419.2414
Slightly volatile
Days Of Payables Outstanding13.1 K12.5 K4.8 K
Slightly volatile
Ebt Per Ebit1.170.94441.0589
Pretty Stable
Company Equity Multiplier0.931.29931.1307
Very volatile
Long Term Debt To Capitalization0.00610.00640.0364
Slightly volatile
Total Debt To Capitalization0.00610.00640.0364
Slightly volatile
Debt Equity Ratio0.00610.00650.0387
Slightly volatile
Quick Ratio4.144.358211.2112
Slightly volatile
Net Income Per E B T0.410.430.8809
Slightly volatile
Cash Ratio4.04.210910.1113
Slightly volatile
Days Of Inventory Outstanding31.2132.8615.4 K
Slightly volatile
Days Of Sales Outstanding1.5 K1.7 K1.8 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00261.0226
Pretty Stable
Price To Book Ratio2.382.510419.2414
Slightly volatile
Fixed Asset Turnover0.180.20.2168
Slightly volatile
Debt Ratio0.00470.0050.034
Slightly volatile
Price Sales Ratio1 K1.2 K1.3 K
Slightly volatile
Asset Turnover7.0E-48.0E-49.0E-4
Slightly volatile
Price Fair Value2.382.510419.2414
Slightly volatile

Cardiol Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap93.1 M49.6 M87.3 M
Slightly volatile

Cardiol Fundamental Market Drivers

Cash And Short Term Investments34.9 M

Cardiol Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cardiol Therapeutics Financial Statements

Cardiol Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Cardiol Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-7.6 M-7.2 M
Cost Of Revenue248.4 K233.3 K
Stock Based Compensation To Revenue 97.11  86.32 
Sales General And Administrative To Revenue 318.51  283.12 
Research And Ddevelopement To Revenue 124.22  110.42 
Capex To Revenue 0.15  0.13 
Ebit Per Revenue(519.63)(545.61)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports:
How To Invest In Cardiol
Details
Is Cardiol Stock a good investment?
Details
What is Cardiol Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Cardiol Therapeutics Correlation against competitors.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.38)
Return On Assets
(0.54)
Return On Equity
(1.08)
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY